ARTICLE | Politics & Policy
FDA revises guidance for HCV therapies
October 17, 2013 12:03 AM UTC
FDA now recommends using sustained virologic response (SVR) at 12 weeks after the end of treatment as the primary endpoint in registration trials of chronic HCV therapies, according to revised draft (...